Home › Funds › GordonMD Global Investments LP › RARE
GordonMD Global Investments LP position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
GordonMD Global Investments LP reported holding 289,101 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$9.7M, representing 4.67% of its reported portfolio and ranking #9 among its reported holdings. GordonMD Global Investments LP has disclosed RARE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How GordonMD Global Investments LP's RARE position evolved
GordonMD Global Investments LP first disclosed a stake in RARE in Q4 2025 at 329,101 shares (US$7.6M). The position peaked in Q2 2026 at 289,101 shares, worth US$9.7M. Across 3 filings, GordonMD Global Investments LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 289,101 shares valued at US$9.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 329.10K | $7.57M | New |
| Q1 2026 | 289.10K | $6.06M | Reduce |
| Q2 2026 | 289.10K | $9.65M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 27 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 7.80M sh · $260.34M · Q2 2026
- SANDS CAPITAL MANAGEMENT, LLC 3.16M sh · $105.46M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026
More on GordonMD Global Investments LP
FAQ
How long has GordonMD Global Investments LP held RARE?
GordonMD Global Investments LP has disclosed RARE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is GordonMD Global Investments LP's current position in RARE?
As of Q2 2026, GordonMD Global Investments LP holds 289.10K shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $9.65M, representing 4.67% of its reported portfolio and ranking #9.
Has GordonMD Global Investments LP been buying or selling RARE?
In the latest 13F filing (Q2 2026), GordonMD Global Investments LP held unchanged its position in RARE. The position peaked in Q2 2026 at 289.10K shares.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, FRONTIER CAPITAL MANAGEMENT CO LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.